ストックスクリーナーアプリを入手
1.87
2.09%
-0.04
アフターアワーズ：
1.87
前日終値:
$1.91
開ける：
$1.9
24時間の取引高:
1.03M
Relative Volume:
0.84
時価総額：
$94.88M
収益：
-
当期純損益:
$-67.68M
株価収益率:
-1.1265
EPS:
-1.66
ネットキャッシュフロー:
$-54.24M
1週間 パフォーマンス:
+6.86%
1か月 パフォーマンス:
+46.09%
6か月 パフォーマンス:
-51.05%
1年 パフォーマンス:
-81.17%
1日の値動き範囲:
$1.815
$1.99
1週間の範囲:
$1.68
$1.99
52週間の値動き範囲:
$0.9857
$13.50
Cabaletta Bio Inc Stock (CABA) Company Profile
CABA を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CABA
Cabaletta Bio Inc
|
1.87 | 88.80M | 0 | -67.68M | -54.24M | -1.66 |
|
ONC
Beone Medicines Ltd Adr
|
245.58 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
442.05 | 111.96B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 42.96M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
81.20 | 6.39B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.28 | 63.52B | 14.09B | 4.50B | 2.96B | 39.28 |
Cabaletta Bio Inc Stock (CABA) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-12-20 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2024-12-19 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2024-10-10 | 開始されました | UBS | Buy |
| 2024-02-05 | 開始されました | Jefferies | Buy |
| 2023-11-29 | 開始されました | William Blair | Outperform |
| 2023-10-24 | 開始されました | Cantor Fitzgerald | Overweight |
| 2023-10-19 | 開始されました | Stifel | Buy |
| 2023-09-05 | 開始されました | Citigroup | Buy |
| 2023-07-18 | 開始されました | Guggenheim | Buy |
| 2023-01-27 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2022-08-30 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2021-12-08 | 開始されました | Wells Fargo | Overweight |
| 2021-10-19 | 再開されました | Morgan Stanley | Overweight |
| 2021-06-30 | 開始されました | Mizuho | Buy |
| 2021-01-08 | 開始されました | Chardan Capital Markets | Buy |
| 2020-10-13 | 開始されました | H.C. Wainwright | Buy |
| 2019-11-19 | 開始されました | Cowen | Outperform |
| 2019-11-19 | 開始されました | Evercore ISI | Outperform |
| 2019-11-19 | 開始されました | Morgan Stanley | Overweight |
すべてを表示
Cabaletta Bio Inc (CABA) 最新ニュース
Two Sigma Advisers LP Purchases 550,700 Shares of Cabaletta Bio, Inc. (NASDAQ:CABA) - MarketBeat
Cabaletta Bio to Present at Jefferies Global Healthcare Conference 2025 - MSN
Northern Trust Corp Sells 5,849 Shares of Cabaletta Bio, Inc. (NASDAQ:CABA) - Defense World
Cabaletta Bio to Present at Jefferies Global Healthcare Conference on June 4, 2025 - Nasdaq
Cabaletta Bio to Participate in the Jefferies Global Healthcare Conference - The Manila Times
D. E. Shaw & Co. Inc. Sells 17,359 Shares of Cabaletta Bio, Inc. (NASDAQ:CABA) - Defense World
Analysts Set Cabaletta Bio, Inc. (NASDAQ:CABA) Price Target at $20.33 - MarketBeat
Cabaletta Bio Updates Progress on RESET-Myositis Trial and Regulatory Milestones - MSN
Point72 Asset Management L.P. Acquires 598,607 Shares of Cabaletta Bio, Inc. (NASDAQ:CABA) - MarketBeat
Cabaletta Bio (NASDAQ:CABA) Announces Quarterly Earnings Results - MarketBeat
Cantor Fitzgerald Predicts Weaker Earnings for Cabaletta Bio - MarketBeat
Cabaletta Bio Reprices Stock Options to Motivate Staff - MSN
Cabaletta Bio, Inc. (NASDAQ:CABA) Given Average Recommendation of “Buy” by Analysts - Defense World
Raiffeisen Bank International AG Invests $493,000 in Cabaletta Bio, Inc. (NASDAQ:CABA) - MarketBeat
Cabaletta Bio, Inc. (NASDAQ:CABA) Shares Sold by Cubist Systematic Strategies LLC - MarketBeat
Cantor Fitzgerald Estimates Cabaletta Bio FY2025 Earnings - Defense World
Cabaletta Bio announces option repricing for key personnel By Investing.com - Investing.com India
CABA FRAUD ALERT: Hagens Berman, National Trial Attorneys, Encourages Cabaletta Bio (CABA) Investors with Significant Losses to Contact Firm’s Attorneys, Securities Fraud Class Action Filed - ACCESS Newswire
Cabaletta Bio announces option repricing for key personnel - Investing.com
Cabaletta Bio (CABA) Projected to Post Earnings on Wednesday - MarketBeat
Citigroup Lowers Cabaletta Bio (NASDAQ:CABA) Price Target to $13.00 - Defense World
Guggenheim Forecasts Strong Price Appreciation for Cabaletta Bio (NASDAQ:CABA) Stock - Defense World
Cabaletta Bio Inc reports results for the quarter ended March 31Earnings Summary - TradingView
CABA Stock News: Citigroup Lowers Price Target but Maintains Buy - GuruFocus
CABA: Guggenheim Raises Price Target for Cabaletta Bio to $25 | - GuruFocus
UBS Adjusts Price Target on Cabaletta Bio to $6 From $7, Maintains Buy Rating - marketscreener.com
Spotlight On Silence Therapeutics And 2 Other Promising Penny Stocks - simplywall.st
Cabaletta Bio’s Strategic Advancements and Trial Successes Drive Buy Rating - TipRanks
Cabaletta Bio (CABA) Price Target Slashed by Citi, Keeps Buy Rat - GuruFocus
Cabaletta Bio (CABA) Price Target Slashed by Citi, Keeps Buy Rating | CABA Stock News - GuruFocus
Cabaletta Bio Extends Gains Premarket as FDA Meeting Fuels Expectations for Myositis BLA Submission - marketscreener.com
41,626 Shares in Cabaletta Bio, Inc. (NASDAQ:CABA) Acquired by Stifel Financial Corp - Defense World
Cabaletta Bio Stock Surges To 2-Month High On Autoimmune Therapy Progress; Retail’s Pleased - Asianet Newsable
CABA: Guggenheim Raises Price Target to $25, Maintains Buy Ratin - GuruFocus
Fred Alger Management LLC Sells 1,803,170 Shares of Cabaletta Bio, Inc. (NASDAQ:CABA) - MarketBeat
CABA: Guggenheim Raises Price Target to $25, Maintains Buy Rating | CABA Stock News - GuruFocus
Guggenheim Increases Price Target for Cabaletta Bio (CABA) to $2 - GuruFocus
Guggenheim Increases Price Target for Cabaletta Bio (CABA) to $25 | CABA Stock News - GuruFocus
Cabaletta Bio (CABA) Targets 2027 for Rese-cel BLA Submission | - GuruFocus
Cabaletta Bio Inc (CABA) Reports Q1 EPS Miss at -0.64, No Revenue Recorded - GuruFocus
Cabaletta Bio Announces 2027 Rese-Cel BLA Submission Anticipated In Myositis Following Recent FDA Alignment On Registrational Cohorts - marketscreener.com
Cabaletta Bio Announces 2027 BLA Plans for Rese-cel - TipRanks
Cabaletta Bio, Inc. SEC 10-Q Report - TradingView
Cabaletta Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
Cabaletta Bio Announces 2027 Rese-cel BLA Submission Anticipated in Myositis Following Recent ... - Eagle-Tribune
Cabaletta Bio Announces 2027 Rese-cel BLA Submission Anticipated in Myositis Following Recent FDA Alignment on Registrational Cohorts - Yahoo Finance
Barclays PLC Boosts Stake in Cabaletta Bio, Inc. (NASDAQ:CABA) - Defense World
Cabaletta Bio (CABA) to Release Quarterly Earnings on Wednesday - Defense World
Wells Fargo & Company MN Purchases 16,250 Shares of Cabaletta Bio, Inc. (NASDAQ:CABA) - Defense World
Cabaletta Bio Inc (CABA) 財務データ
収益
当期純利益
現金流量
EPS
1.89%
3.74%
大文字化:
|
ボリューム (24 時間):